Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
作者信息
Heine Robert J, Fu Haoda, Kendall David M, Moller David E
机构信息
Lilly Research Laboratories and Lilly Diabetes, Eli Lilly & Co., Indianapolis, Indiana.
出版信息
Diabetes. 2013 Oct;62(10):e16-7. doi: 10.2337/db13-0690.
Abstract
摘要
相似文献
1
Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.评论：巴特勒等人。在患有外分泌胰腺发育异常增加及存在产生胰高血糖素的神经内分泌肿瘤可能性的人类中，肠促胰岛素疗法可使外分泌和内分泌胰腺显著扩张。《糖尿病》2013年；62卷：2595 - 2604页。
Diabetes. 2013 Oct;62(10):e16-7. doi: 10.2337/db13-0690.
2
Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.评论：巴特勒等人。在患有外分泌胰腺发育异常增加且有产生胰高血糖素的神经内分泌肿瘤潜在风险的人类中，肠促胰岛素疗法使外分泌和内分泌胰腺显著扩张。《糖尿病》2013年；62卷：2595 - 2604页。
Diabetes. 2013 Oct;62(10):e18. doi: 10.2337/db13-0525.
3
Response to comments on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.对关于以下内容的评论的回应：巴特勒等人。在患有外分泌胰腺发育异常增加和产生胰高血糖素的神经内分泌肿瘤潜在风险的人类中，肠促胰岛素治疗使外分泌和内分泌胰腺显著扩张。《糖尿病》2013年；62卷：2595 - 2604页。
Diabetes. 2013 Oct;62(10):e19-22. doi: 10.2337/db13-0996.
4
Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.外分泌和内分泌胰腺在具有外分泌胰腺发育不良增加的人类中随着肠促胰岛素治疗而显著扩张，并且具有产生胰高血糖素的神经内分泌肿瘤的潜力。
Diabetes. 2013 Jul;62(7):2595-604. doi: 10.2337/db12-1686. Epub 2013 Mar 22.
5
Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.肠促胰岛素疗法对胰腺影响研究的重新分析：方法学缺陷
Diabetes Obes Metab. 2014 Jul;16(7):661-6. doi: 10.1111/dom.12257. Epub 2014 Jan 29.
6
Incretin therapy and islet pathology: a time for caution.肠促胰岛素治疗与胰岛病理学：需谨慎对待的时候了。
Diabetes. 2013 Jul;62(7):2178-80. doi: 10.2337/db13-0520. Epub 2013 Apr 17.
7
Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.接受基于肠促胰岛素疗法的患者胰腺内分泌和外分泌组织的组织学变化。
Diabetes Obes Metab. 2016 Dec;18(12):1253-1262. doi: 10.1111/dom.12766. Epub 2016 Sep 26.
8
Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.肠促胰岛素疗法不会增加年轻雄性小鼠的β细胞量或改变胰腺组织学。
Endocrinology. 2017 Jun 1;158(6):1701-1714. doi: 10.1210/en.2017-00027.
9
Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.2型糖尿病患者胰腺中胰高血糖素样肽1受体（GLP-1R）表达的免疫组织化学评估
Diabetes Obes Metab. 2017 May;19(5):705-712. doi: 10.1111/dom.12879. Epub 2017 Mar 10.
10
Lipotoxicity impairs incretin signalling.脂毒性损害肠促胰岛素信号转导。
Diabetologia. 2013 Feb;56(2):231-3. doi: 10.1007/s00125-012-2788-6. Epub 2012 Nov 28.
引用本文的文献
1
Incretins and SGLT-2 inhibitors in diabetic patients with neuroendocrine tumors: current updates and future directions.糖尿病合并神经内分泌肿瘤患者的肠促胰岛素和钠-葡萄糖协同转运蛋白2抑制剂：最新进展与未来方向
Rev Endocr Metab Disord. 2025 Apr 2. doi: 10.1007/s11154-025-09958-5.
2
Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.肠促胰岛素疗法不会增加年轻雄性小鼠的β细胞量或改变胰腺组织学。
Endocrinology. 2017 Jun 1;158(6):1701-1714. doi: 10.1210/en.2017-00027.
3
Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues.胰高血糖素样肽-1受体在正常及肿瘤性人类胰腺组织中的表达
Pancreas. 2016 Apr;45(4):613-9. doi: 10.1097/MPA.0000000000000521.
4
Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!研究基于肠促胰岛素的疗法所引发的胰腺风险：这是一场游戏吗？这可不是一场游戏！
J Diabetes Sci Technol. 2014 Jul;8(4):895-7. doi: 10.1177/1932296814532874. Epub 2014 May 12.
5
Action and therapeutic potential of oxyntomodulin.胃泌酸调节素的作用及治疗潜力。
Mol Metab. 2013 Dec 14;3(3):241-51. doi: 10.1016/j.molmet.2013.12.001. eCollection 2014 Jun.
6
A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor.一种新型人源化GLP-1受体模型能够实现受体的亲和纯化和Cre-LoxP缺失。
PLoS One. 2014 Apr 2;9(4):e93746. doi: 10.1371/journal.pone.0093746. eCollection 2014.
7
Response to comments on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.对关于以下内容的评论的回应：巴特勒等人。在患有外分泌胰腺发育异常增加和产生胰高血糖素的神经内分泌肿瘤潜在风险的人类中，肠促胰岛素治疗使外分泌和内分泌胰腺显著扩张。《糖尿病》2013年；62卷：2595 - 2604页。
Diabetes. 2013 Oct;62(10):e19-22. doi: 10.2337/db13-0996.
本文引用的文献
1
Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.外分泌和内分泌胰腺在具有外分泌胰腺发育不良增加的人类中随着肠促胰岛素治疗而显著扩张，并且具有产生胰高血糖素的神经内分泌肿瘤的潜力。
Diabetes. 2013 Jul;62(7):2595-604. doi: 10.2337/db12-1686. Epub 2013 Mar 22.
2
No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.在接受 exenatide 治疗 13 周的大鼠中未发现药物引起的胰腺炎的证据。
Diabetes Obes Metab. 2013 May;15(5):417-26. doi: 10.1111/dom.12040. Epub 2012 Dec 7.
3
The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.利拉鲁肽治疗对雄性和雌性 ZDF 大鼠内分泌和外分泌胰腺的影响：一项定量和定性分析，未发现药物引起胰腺炎的证据。
Am J Physiol Endocrinol Metab. 2012 Jul 15;303(2):E253-64. doi: 10.1152/ajpendo.00182.2012. Epub 2012 May 15.
4
Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.外源性 GLP-1 受体激动剂 exendin-4 持续激活可诱导大鼠胰管腺扩张，并加速 Kras(G12D) 小鼠模型中发育不良病变和慢性胰腺炎的形成。
Diabetes. 2012 May;61(5):1250-62. doi: 10.2337/db11-1109. Epub 2012 Jan 20.
5
Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents.艾塞那肽不会引起胰腺炎，并能减轻正常和糖尿病啮齿动物的化学诱导性胰腺炎。
Am J Physiol Endocrinol Metab. 2010 Dec;299(6):E1076-86. doi: 10.1152/ajpendo.00479.2010. Epub 2010 Oct 5.
6
Beta-cell replication is increased in donor organs from young patients after prolonged life support.β细胞在经过长时间生命支持后，来自年轻患者的供体器官中的复制增加。
Diabetes. 2010 Jul;59(7):1702-8. doi: 10.2337/db09-1698. Epub 2010 Apr 22.
7
The prevalence of pancreatic intraepithelial neoplasia in pancreata with uncommon types of primary neoplasms.具有罕见类型原发性肿瘤的胰腺中胰腺上皮内瘤变的患病率。
Am J Surg Pathol. 2006 Jan;30(1):36-41. doi: 10.1097/01.pas.0000180440.41280.a5.
8
Pancreatic fibrosis associated with age and ductal papillary hyperplasia.与年龄及导管乳头状增生相关的胰腺纤维化。
Virchows Arch. 2005 Nov;447(5):800-5. doi: 10.1007/s00428-005-0032-1. Epub 2005 Jul 14.
Zotero 插件